SMTL ID : 7uhc.1

SARS-CoV-2 spike in complex with AHB2-2GS-SB175

Coordinates

PDB Format Compare

Method

ELECTRON MICROSCOPY

Oligo State

hetero-3-3-mer

Ligands

12 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)

NAG-NAG.1: 4 residues within 4Å: Chain A: N.717, L.922, Q.926, Q.1071 1 PLIP interactions: 1 interactions with chain A Hydrophobic interactions: A:L.922 NAG-NAG.2: 2 residues within 4Å: Chain A: N.801, Q.804 No protein-ligand interaction detected (PLIP) NAG-NAG.3: 3 residues within 4Å: Chain A: N.1098, H.1101, F.1103 No protein-ligand interaction detected (PLIP) NAG-NAG.4: 1 residues within 4Å: Chain A: N.1134 No protein-ligand interaction detected (PLIP) NAG-NAG.5: 4 residues within 4Å: Chain C: N.717, L.922, Q.926, Q.1071 1 PLIP interactions: 1 interactions with chain C Hydrophobic interactions: C:L.922 NAG-NAG.6: 2 residues within 4Å: Chain C: N.801, Q.804 No protein-ligand interaction detected (PLIP) NAG-NAG.7: 3 residues within 4Å: Chain C: N.1098, H.1101, F.1103 No protein-ligand interaction detected (PLIP) NAG-NAG.8: 1 residues within 4Å: Chain C: N.1134 No protein-ligand interaction detected (PLIP) NAG-NAG.9: 4 residues within 4Å: Chain E: N.717, L.922, Q.926, Q.1071 1 PLIP interactions: 1 interactions with chain E Hydrophobic interactions: E:L.922 NAG-NAG.10: 2 residues within 4Å: Chain E: N.801, Q.804 No protein-ligand interaction detected (PLIP) NAG-NAG.11: 3 residues within 4Å: Chain E: N.1098, H.1101, F.1103 No protein-ligand interaction detected (PLIP) NAG-NAG.12: 1 residues within 4Å: Chain E: N.1134 No protein-ligand interaction detected (PLIP)

36 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)

NAG.13: 1 residues within 4Å: Chain A: N.61 Ligand excluded by PLIP NAG.14: 3 residues within 4Å: Chain A: N.122, A.123, T.124 Ligand excluded by PLIP NAG.15: 3 residues within 4Å: Chain A: G.232, I.233, N.234 Ligand excluded by PLIP NAG.16: 1 residues within 4Å: Chain A: N.282 Ligand excluded by PLIP NAG.17: 3 residues within 4Å: Chain A: N.331, P.579, Q.580 Ligand excluded by PLIP NAG.18: 1 residues within 4Å: Chain A: N.603 Ligand excluded by PLIP NAG.19: 3 residues within 4Å: Chain A: N.616, T.618, Q.644 Ligand excluded by PLIP NAG.20: 1 residues within 4Å: Chain A: N.657 Ligand excluded by PLIP NAG.21: 2 residues within 4Å: Chain A: N.709, G.1131 Ligand excluded by PLIP NAG.22: 3 residues within 4Å: Chain A: A.706, E.1072, N.1074 Ligand excluded by PLIP NAG.23: 2 residues within 4Å: Chain A: Q.115, N.165 Ligand excluded by PLIP NAG.24: 4 residues within 4Å: Chain A: F.338, G.339, N.343, V.367 Ligand excluded by PLIP NAG.25: 1 residues within 4Å: Chain C: N.61 Ligand excluded by PLIP NAG.26: 3 residues within 4Å: Chain C: N.122, A.123, T.124 Ligand excluded by PLIP NAG.27: 3 residues within 4Å: Chain C: G.232, I.233, N.234 Ligand excluded by PLIP NAG.28: 1 residues within 4Å: Chain C: N.282 Ligand excluded by PLIP NAG.29: 3 residues within 4Å: Chain C: N.331, P.579, Q.580 Ligand excluded by PLIP NAG.30: 1 residues within 4Å: Chain C: N.603 Ligand excluded by PLIP NAG.31: 3 residues within 4Å: Chain C: N.616, T.618, Q.644 Ligand excluded by PLIP NAG.32: 1 residues within 4Å: Chain C: N.657 Ligand excluded by PLIP NAG.33: 2 residues within 4Å: Chain C: N.709, G.1131 Ligand excluded by PLIP NAG.34: 3 residues within 4Å: Chain C: A.706, E.1072, N.1074 Ligand excluded by PLIP NAG.35: 2 residues within 4Å: Chain C: Q.115, N.165 Ligand excluded by PLIP NAG.36: 4 residues within 4Å: Chain C: F.338, G.339, N.343, V.367 Ligand excluded by PLIP NAG.37: 1 residues within 4Å: Chain E: N.61 Ligand excluded by PLIP NAG.38: 3 residues within 4Å: Chain E: N.122, A.123, T.124 Ligand excluded by PLIP NAG.39: 3 residues within 4Å: Chain E: G.232, I.233, N.234 Ligand excluded by PLIP NAG.40: 1 residues within 4Å: Chain E: N.282 Ligand excluded by PLIP NAG.41: 3 residues within 4Å: Chain E: N.331, P.579, Q.580 Ligand excluded by PLIP NAG.42: 1 residues within 4Å: Chain E: N.603 Ligand excluded by PLIP NAG.43: 3 residues within 4Å: Chain E: N.616, T.618, Q.644 Ligand excluded by PLIP NAG.44: 1 residues within 4Å: Chain E: N.657 Ligand excluded by PLIP NAG.45: 2 residues within 4Å: Chain E: N.709, G.1131 Ligand excluded by PLIP NAG.46: 3 residues within 4Å: Chain E: A.706, E.1072, N.1074 Ligand excluded by PLIP NAG.47: 2 residues within 4Å: Chain E: Q.115, N.165 Ligand excluded by PLIP NAG.48: 4 residues within 4Å: Chain E: F.338, G.339, N.343, V.367 Ligand excluded by PLIP

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Hunt, A.C. et al., Multivalent designed proteins neutralize SARS-CoV-2 variants of concern and confer protection against infection in mice. Sci Transl Med (2022)

Release Date

2022-06-08

Peptides

Spike glycoprotein: ACE
Multivalent miniprotein inhibitor AHB2-2GS-SB175: BDF

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

C
B

E
D

B
K

D
C

F
E

Spike glycoprotein

Multivalent miniprotein inhibitor AHB2-2GS-SB175

Related Entries With Identical Sequence